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ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening hematological abnormality characterized by 
thrombocytopenia and microangiopathic hemolytic anemia, with neurological abnormalities and/or renal disease. TTP 
has been rarely reported in juvenile systemic lupus erythematosus (JSLE) patients and, to our knowledge, its prevalence 
in a paediatric lupus population has not been studied. Therefore, from January 1983 to December 2010, we reviewed 
the charts of 5,508 patients followed-up at the Paediatric Rheumatology Unit of our university hospital. We identi¿ ed 
279 (5.1%) JSLE cases that met the American College of Rheumatology classi¿ cation criteria. Two (0.7%) of them had 
TTP, both at JSLE onset, and were described herein. Both patients had fever, microangiopathic hemolytic anemia (with 
schistocytes in blood smears), and thrombocytopenia. The male patient had hemiparesis and proteinuria and the female 
patient had persistent headache and hematuria. Both were treated with intravenous methylprednisolone and courses of 
plasma exchange therapy at TTP diagnosis. After treatment, TTP did not recur and their hematocrit, platelet count, and 
lactic dehydrogenase remained normal. In conclusion, TTP is a rare and severe manifestation at JSLE onset. The case 
reports reinforce the importance of early diagnosis and early aggressive treatment for patients with TTP, due to its high 
morbidity. 
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INTRODUCTION
Juvenile systemic lupus erythematosus (JSLE) is the prototype 
of autoimmune disease and may affect multiple organs and 
systems. Hematologic abnormalities, such as anemia, leuko-
penia, thrombocytopenia, and clotting defects, are well-known 
characteristics of this disease.1 
Thrombotic thrombocytopenic purpura (TTP) is a rare 
and life-threatening disease. This hematological disorder is 
characterized by thrombocytopenia, microangiopathic hemo-
lytic anemia, and neurological and/or renal abnormalities.2–5 
Remarkably, it is a microvascular occlusive disorder, with frag-
mented blood cells and schistocytes in the peripheral blood.3 
TTP has been rarely reported in JSLE patients.2–9 This 
manifestation may occur before lupus diagnosis2, at presenta-
tion,3,4,6–8 or during the course of the disease.5,9 However, to 
our knowledge, the prevalence of this severe manifestation in 
paediatric lupus population has not been studied. 
Therefore, we reviewed our data from January 1983 to 
December 2010 and included the 5,508 patients of Paediatric 
Rheumatology Unit, Instituto da Criança, Faculdade de 
Medicina, Universidade de São Paulo. We identi¿ ed 279 
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(5.1%) cases that met the American College of Rheumatology 
(ACR)10 classification criteria for JSLE. Two (0.7%) of 
them had TTP at presentation of JSLE and were described 
herein. These case reports were approved by the Local Ethics 
Committee of our University Hospital.
CASE REPORTS
Case 1
A 10.5 year-old boy had a diffuse petechial rash, oral and 
nasal spontaneous bleeding, macroscopic hematuria, and 
hematemesis, in conjunction with high  fever for 15 days. 
Then, the patient had seizures and was hospitalized in our 
service due to right proportional hemiparesis and dysarthria 
secondary to stroke on left frontal area. He also had anorexia, 
photosensitivity, malar and palmar erythema, arthralgia, and 
hepatomegaly. At that moment, laboratory exams revealed 
hemoglobin 5.7 g/L, hematocrit 17%, reticulocytes 13%, white 
blood cell (WBC) count 4,800/mm³ (64% neutrophils, 31% 
lymphocytes, 2% eosinophils, and 3% monocytes), platelets 
8,000/mm³, lactic dehydrogenase (LDH) 4,069 U/L (normal 
141–231), negative direct Coombs test, D-dimer 4,632 ng/mL 
(normal < 500), C-reactive protein (CRP) 13.5 mg/dL (normal 
< 5), urinalysis with 102,000 erythrocytes and granular casts, 
urea 40 mg/dL, creatinine 0.45 mg/dL, proteinuria 1.35 g/day, 
aspartate aminotransferase (AST) 191 IU/L (normal 10–36), 
alanine aminotransferase (ALT) 50 IU/L (normal 24–49), 
gamma-glutamyl transpeptidase (GGT) 49 g/dL (normal 
14–26), total bilirubin 1.94 mg/dL (normal 0–1), indirect 
bilirubin 1.37 mg/dL (normal 0.1–1), ¿ brinogen 241 mg/dL 
(normal 220–496), normal clotting test, albumin 3.7 g/dL 
(normal 3.8–5.6), haptoglobin 75 mg/dL (normal 30–200), C3 
140 mg/dL (normal 67–149), C4 28 mg/dL (normal 10–38), 
and ferritin 3,807 mg/mL (normal 36–311). The blood smears 
showed microangiopathic anemia, with presence of several 
schistocytes. The von Willebrand factor was 316% (normal 
60%–150%). An auto-antibodies analysis revealed positive 
antinuclear antibodies (ANA) 1/160 (speckled pattern), IgG 
anticardiolipin 25 GPL, IgM anticardiolipin 7 MPL, and nega-
tive anti-double stranded DNA (anti-dsDNA), lupus antico-
agulant and anti-Sm antibodies. The carotid ultrasonography 
was normal and the brain computer tomography evidenced 
an ischemic brain vascular accident on the left frontal area. 
Therefore, TTP and JSLE were diagnosed. At that moment, 
the Systemic Lupus Erythematosus Disease Activity Index 
2000 (SLEDAI-2K) score was 32.11 The patient was treated 
with three intravenous methylprednisolone pulses followed 
by prednisone (60 mg/day), nine sequential courses of plasma 
exchange therapy and chloroquine. After that his hemato-
crit, platelet count and LDH remained normal, and without 
evidence of antiphospholipid antibodies. However, he had 
persistent neurological sequelae with hemiparesis and TTP 
remission for a period of 13 months. 
Case 2
A 10.4 year-old girl had pale skin, petechial rash, haemato-
mas, epistaxis, fever, alopecia, vomiting, severe and persistent 
headache, and arthritis in knees for 10 days. She was hospital-
ized, and her laboratory exams revealed hemoglobin 6.4 g/L, 
hematocrit 19%, reticulocytes 18%, WBC count 6,300/mm³ 
(79% neutrophils, 17% lymphocytes, 0% eosinophils, and 4% 
monocytes), platelets 10,000/mm³, LDH 2,700 U/L, negative 
direct Coombs test, D-dimer 1,611 ng/mL, CRP 1.2 mg/dL, 
urinalysis with 42,000 erythrocytes, urea 53 mg/dL, creatinine 
0.48 mg/dL, proteinuria 0.24 g/day, haptoglobin 8 mg/dL, AST 
171 IU/L, ALT 212 IU/L, total bilirubin 2.08 mg/dL, indirect 
bilirubin 1.79 mg/dL, ¿ brinogen 53 mg/dL, normal clotting test, 
albumin 3.2 g/dL, ferritin 500 mg/mL, lipase 290 mg/dL (nor-
mal 145–226), C3 138 mg/dL, and C4 12 mg/dL. Blood smears 
showed microangiopathic anemia with several schistocytes. 
The von Willebrand factor-cleaving protease (ADAMTS-13) 
activity was < 1% (normal > 5%). Brain computer tomogra-
phy and echocardiogram were normal. Immunological tests 
revealed positive ANA 1:1280 (speckled pattern), anti-Sm, 
anti-RNP and IgM anticardiolipin (17 MPL), being negative 
for other serum antibodies: anti-dsDNA, anti-Ro, anti-La, 
IgG anticardiolipin, lupus anticoagulant, anti-nucleosome, 
and anti-ribosomal P antibodies. Therefore, TTP and JSLE 
were diagnosed. At that moment, the SLEDAI-2K score was 
17.11 The patient was treated with three intravenous methyl-
prednisolone pulses followed by prednisone (60 mg/day) and 
18 sequential courses of plasma exchange therapy. After that, 
she was treated with azathioprine and chloroquine. Prednisone 
dose was progressively tapered to 15 mg/day. After six months, 
her hematocrit, platelet count and LDH remained normal with 
TTP remission, and without evidence of antiphospholipid 
antibodies. 
 DISCUSSION
To our knowledge, this is the ¿ rst study that evaluated the 
prevalence of TTP in a large population of JSLE in a tertiary 
Paediatric University Hospital and evidenced a rare prevalence 
of this hematological abnormality at lupus onset. 
TTP is a severe hematological disorder which is char-
acterized by the involvement of the central nervous system 
RBR 53(1).indb   Miolo121 20/03/2013   16:26:06
Campos et al.
122 Rev Bras Reumatol 2013;53(1):120–126
microangiopathic hemolytic anemia, and thrombocytopenia.4,5,9 
Hemolysis with detection of elevated reticulocyte count and/or 
decrease of haptoglobin, and elevated LDH levels have also be 
observed in patients with TTP,7,8,9 as detected in our cases. The 
Coombs test is generally negative, as also evidenced herein.2
Of note, the TTP involvements are similar to lupus mani-
festations, especially neuropsychiatric and renal involvements.2 
Recently the two hematological abnormalities (platelets counts 
lower than 100,000/mm3 concomitantly with microangiopathic 
hemolytic anemia with presence of schistocytes in peripheral 
blood smears) were considered essential to TTP diagnosis, with 
exclusion of other diseases, such as autoimmune hemolytic 
anemia, disseminated intravascular coagulation, cancer, drug 
toxicity, and malignant hypertension.12
In addition, TTP is a microvascular occlusive disorder, 
that may lead to microthrombi and ischemia, particularly in 
brain and renal glomeruli.2,9 In fact, neurological features (such 
as headache,2,6 seizures, hemiparesis,2 and transitory mental 
confusion4) and renal abnormalities2,9 are common clinical 
manifestations of TTP. Importantly, to our information, the 
occurrence of ischemic brain vascular accident with neurologi-
cal sequelae, as evidenced in one of our cases, has not been 
previously described in paediatric lupus population. 
The pathogenesis of TTP is unknown. This abnormality 
may occur due to some genetic de¿ ciency13 or due to the ac-
quired form, which is a result of the presence of autoantibody 
against the protease that cleaves the von Willebrand factor, 
named ADAMTS-13 (a disintegrin and metalloprotease with 
a thrombospondin type 1 motifs 13).9 In fact, the reduction of 
this protease releases the von Willebrand factor multimers and 
determines thrombi formation in this disease.13 
This hematological abnormality can be associated with au-
toimmune disease, in both adult6 and paediatric lupus.2,3 Indeed, 
TTP associated with JSLE and lupus nephritis9 has been rarely 
described, affecting mainly females2–4,6,9 at disease onset.3,4,6–8
The most important differential diagnosis of TTP in lupus 
patients are: macrophage activation syndrome,14  disseminated 
intravascular coagulation, Evans syndrome (autoimmune 
hemolytic anemia and idiopathic thrombocytopenic pur-
pura),9 antiphospholipid antibody syndrome, eclampsia, and 
hemolytic uremic syndrome.12 In the latter, fever is rarely 
observed and renal abnormalities are more severe when 
compared to TTP.9 
The treatment of TTP in JSLE patients consists of con-
comitant plasmapheresis and glucocorticoids therapy2,9 until 
clinical and laboratory improvement, mainly the normalization 
of hematocrit, platelets’ count and LDH9, as evidenced in our 
two cases. The mean number of therapeutic plasma exchange 
sessions reported in the literature varied from 5–14.4,6,7,9 Other 
treatments to refractory or severe TTP associated with lupus 
included immunosuppressive drugs, such as cyclophosphamide 
and mycophenolate mofetil,5 intravenous immunoglobulin8 
and rituximab.9 
Regarding the outcome, death due to multiple organ failure8 
and reminiscent occasional headache2 have also been previ-
ously described. Our case 1 had a relevant ischemic brain 
vascular accident with persistent neurological sequelae.
The possible limitation for this study could be the retro-
spective medical records analysis, and this haematological 
manifestation could be underestimated. A future prospective 
and multicentre study is necessary.
In conclusion, TTP is a rare and severe manifestation at 
lupus onset. The case reports reinforce the importance of early 
diagnosis and early aggressive treatment for patients with TTP 
due to high morbidity. 
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DISCUSSÃO
Até onde sabemos, este é o primeiro estudo a avaliar a prevalên-
cia de PTT em uma grande população de LESJ de um hospital 
universitário pediátrico terciário, tendo evidenciado uma rara 
prevalência dessa alteração hematológica quando da instalação 
de lúpus. 
A PTT é um distúrbio hematológico grave que se caracteriza 
por envolvimento do sistema nervoso central, anemia hemolítica 
microangiopática e trombocitopenia.4,5,9 Hemólise com contagem 
elevada de reticulócitos e/ou diminuição da haptoglobina e níveis 
altos de LDH também foram relatados em pacientes com PTT,7,8,9 
como visto nos nossos casos. O teste de Coombs é geralmente 
negativo, como foi nos nossos casos.2
É importante ressaltar que as manifestações da PTT são 
semelhantes às do lúpus, em especial as neuropsiquiátricas e 
renais.2 Recentemente, as duas alterações hematológicas (con-
tagem de plaquetas inferior a 100.000/mm3 concomitante com 
anemia hemolítica microangiopática e esquizócitos em esfrega-
ços de sangue periférico) foram consideradas essenciais para o 
diagnóstico de PTT, excluindo-se outras doenças, como anemia 
hemolítica autoimune, coagulação intravascular disseminada, 
câncer, toxicidade a drogas e hipertensão maligna.12
Além disso, a PTT é um distúrbio microvascular oclusivo, 
que pode levar a microtrombos e isquemia, particularmente no 
cérebro, e glomérulos renais.2,9 Na verdade, as alterações neuro-
lógicas (cefaleia,2,6 convulsões, hemiparesia2 e confusão mental 
transitória4) e renais2,9 são manifestações clínicas comuns da PTT. 
É importante notar que a ocorrência de acidente vascular cerebral 
isquêmico com sequelas neurológicas, como evidenciado em 
um de nossos casos, não foi previamente descrita na população 
pediátrica com lúpus. 
A patogênese da PTT é desconhecida. Essa anormalidade 
pode decorrer de alguma de¿ ciência genética13 ou ser adquirida, 
resultando da presença de autoanticorpos contra a protease que 
cliva o fator de von Willebrand, a ADAMTS-13 (uma desinte-
grina e metaloproteinase com domínio trombospondina tipo 1).9 
A redução dessa protease libera multímeros do fator de von 
Willebrand e determina a formação de trombos nessa doença.13 
Essa anormalidade hematológica pode se associar a doença 
autoimune, tanto no lúpus adulto6 quanto pediátrico.2,3 A descri-
ção de PTT associada à LESJ e à nefrite lúpica9 é rara, afetando 
principalmente o sexo feminino2–4,6,9 no início da doença.3,4,6–8
Os diagnósticos diferenciais mais importantes da PTT em 
pacientes com lúpus são: síndrome de ativação macrofágica;14  co-
agulação intravascular disseminada; síndrome de Evans (anemia 
hemolítica autoimune e púrpura trombocitopênica idiopática);9 
síndrome do anticorpo antifosfolípide; eclampsia; e síndrome 
hemolítico-urêmica.12 Na última, a febre é rara e as alterações 
renais são mais graves que na PTT.9 
O tratamento da PTT em pacientes com LESJ consiste em 
plasmaferese concomitante com terapia com glicocorticoides,2,9 
até melhora clínica e laboratorial, em especial normalização de 
hematócrito, contagem de plaquetas e LDH,9 como visto nos 
nossos dois casos. O número médio de sessões de plasmaferese 
relatado na literatura variou de 5 a 14.4,6,7,9  Outros tratamentos 
para PTT refratária ou grave associada com lúpus incluíram imu-
nossupressores, como ciclofosfamida e micofenolato mofetil,5 
imunoglobulina endovenosa8 e rituximabe.9 
Com relação ao desfecho, morte por falência de múltiplos 
órgãos8 e cefaleia reminiscente ocasional2 também já foram des-
critas. No nosso primeiro caso, houve um importante acidente 
vascular cerebral isquêmico com persistente sequela neurológica.
Uma limitação deste estudo pode ter sido a análise retros-
pectiva de dados médicos, com subestimação da manifestação 
hematológica. Um estudo prospectivo e multicêntrico se faz 
necessário.
Concluindo, a PTT é uma manifestação rara e grave no 
início do lúpus. Os casos relatados reforçam a importância do 
diagnóstico precoce e tratamento agressivo de pacientes com 
PTT devido à sua alta morbidade. 
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